Skip to main content

NeuroPace Inc

corporate_fare Company Profile

NeuroPace Inc

NPCE·NASDAQ·Industrial Applications And Services·CIK 0001528287

NeuroPace, Inc. is a medical device company that aims to improve the lives of individuals with epilepsy by reducing or eliminating seizures. The company's primary product is the RNS System, a brain-responsive neuromodulation system. This system is designed to provide personalized, real-time treatment at the source of seizures. It works by continuously monitoring and analyzing the brain's electrical activity, identifying patient-specific abnormal electrical patterns, and responding with electrical pulses to prevent seizures. Clinicians program the RNS System to deliver precise therapy, resulting in approximately three minutes of stimulation on average per day. The RNS System is also the only commercially available device that records continuous brain activity data, enabling clinicians to monitor patients both in person and remotely. This data helps clinicians make more informed treatment decisions. As of December 31, 2025, over 8,000 patients have received the RNS System. The company targets the approximately 575,000 adults in the United States with drug-resistant focal epilepsy and seeks to expand its indication to cover the entire approximately 1.2 million drug-resistant epilepsy patients in the United States. NeuroPace may also expand globally to reach the approximately 16.5 million drug-resistant epilepsy patients worldwide. Epilepsy is a chronic disorder where the brain produces abnormal electrical bursts causing seizures, and treatment aims to reduce seizure frequency and intensity without side effects.

NeuroPace Inc (NASDAQ:NPCE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 14 items for NPCE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for NPCE spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • NeuroPace Halves as Guidance Cut and Q3 Revenue Miss Hit Largest Accounts
  • NeuroPace 10-Q Backs Q3 Results; Cash $49.2M vs $59.2M Debt, Covenants Intact
  • NeuroPace Slashes FY26 Revenue Outlook to $91-92M as Q3 Sales Fall 1.1%
  • NeuroPace Q2 Revenue Jumps 17% to $22.8M, Loss Narrows; Cash Runway Solid
  • NeuroPace Beats Q2 Revenue, Raises 2026 Guidance on RNS Adoption

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$99.99M
Net Income
-$21.46M
Diluted EPS
-$0.66
Op. Cash Flow
-$11.01M
Free Cash Flow
-$11.34M
Gross Profit
$77.22M
Operating Income
-$16.34M
Cash & Equivalents
$21.69M
Total Debt
$58.88M
Debt / Equity
3.09×
Net Margin
-21.5%
Shares Outstanding
33.57M sh
Source: 10-K · filed 2026-03-03 · accession 0001528287-26-000011

Short Interest & Short Volume

8.48 days to cover

FINRA reported short interest of 858,343 shares in NPCE as of the October 30, 2026 settlement, a 3.1% decrease from the prior period — about 8.5 days to cover at its recent average daily volume. On November 20, 2026, 50.9% of NPCE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)858,343 shares as of October 30, 2026
Change vs prior period▼ 3.1%
Days to cover8.48 at avg daily volume of 101,274
Daily short volume (FINRA facilities)50.9% of 132,189 shares on November 20, 2026
5-day average short volume46.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with N →
$7.95
52-week range · as of 2026-11-12 $7.95 – $19.6
Market cap
$273.89M
Volume
749.4K (1.8× avg)
3-mo avg 427.6K
Live data · 2026-11-21 17:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NPCE - Latest Insights

NPCE
Nov 13, 2026, 11:54 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $5.92
Real-time Price: $7.95 info
Change: +$2.03 (+34%) info
Market Cap: $273.89M info
NPCE
Nov 12, 2026, 4:38 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.84
Real-time Price: $7.95 info
Change: +$0.110 (+1%) info
Market Cap: $273.89M info
NPCE
Nov 12, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $12.02
Real-time Price: $7.95 info
Change: -$4.07 (-34%) info
Market Cap: $273.89M info
NPCE
Aug 11, 2026, 4:33 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.03
Real-time Price: $7.95 info
Change: -$7.08 (-47%) info
Market Cap: $273.89M info
NPCE
Aug 11, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $15.03
Real-time Price: $7.95 info
Change: -$7.08 (-47%) info
Market Cap: $273.89M info
NPCE
Aug 11, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.03
Real-time Price: $7.95 info
Change: -$7.08 (-47%) info
Market Cap: $273.89M info
NPCE
Jul 28, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.26
Real-time Price: $7.95 info
Change: -$4.31 (-35%) info
Market Cap: $273.89M info
NPCE
Jul 28, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $13.49
Real-time Price: $7.95 info
Change: -$5.54 (-41%) info
Market Cap: $273.89M info
NPCE
May 12, 2026, 4:45 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.80
Real-time Price: $7.95 info
Change: -$7.85 (-50%) info
Market Cap: $273.89M info
NPCE
May 12, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.80
Real-time Price: $7.95 info
Change: -$7.85 (-50%) info
Market Cap: $273.89M info
NPCE
May 12, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $15.80
Real-time Price: $7.95 info
Change: -$7.85 (-50%) info
Market Cap: $273.89M info
NPCE
Mar 03, 2026, 4:54 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $15.51
Real-time Price: $7.95 info
Change: -$7.56 (-49%) info
Market Cap: $273.89M info
NPCE
Mar 03, 2026, 4:23 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $15.40
Real-time Price: $7.95 info
Change: -$7.45 (-48%) info
Market Cap: $273.89M info
NPCE
Mar 03, 2026, 4:19 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.00
Real-time Price: $7.95 info
Change: -$7.05 (-47%) info
Market Cap: $273.89M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets